$OURA

Oura smart ring IPO roadshow launches, targets $2.2 billion

Oura Health launched its IPO, aiming to raise $2.2B by selling 50M shares at $40-$44 each, targeting a $15.62B valuation. Trading under 'OURA' on Nasdaq, it sold 3.6M rings in the past year with $1.21B revenue. Eli Lilly and Dragoneer may invest $100M and $300M respectively. The company faces a lawsuit over sleep tracking accuracy claims.

Original reporting
Published Sep 21, 2026, 6:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 6:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oura smart ring IPO roadshow launches, targets $2.2 billion — source image
Decision brief

The 30-second read

$OURANeutralHigh
01

Why it matters

The IPO provides a fresh entry point for investors and may set a pricing benchmark for wearable tech firms.

02

Market read

A sizable IPO in the consumer health sector amid a cautious market environment.

03

What to watch

Potential dilution from underwriter option and existing shareholder sell‑down could pressure price.

Relevance 9/10Novelty 9/10Timing: IPO launch today

Background

Oura, a Finnish‑origin health‑tracking ring maker, moved headquarters to San Francisco and seeks a $15.6 billion valuation.

Company-level read

Ticker impact

$OURANeutralHigh confidence
Context

Oura announced its IPO filing on Nasdaq, targeting up to $2.2 billion by selling 50 million shares.

Expected impact

Initial pricing pressure likely modest; post‑IPO volatility expected.

Evidence & confidence

Primary disclosure of a multi‑billion IPO for a mid‑cap company; scale and novelty drive relevance.

Market effects

Highlights growing interest in consumer health wearables and may boost peer valuations.

Adds a new tech listing to the Nasdaq, modest effect on US markets.

Signals continued appetite for IPOs despite broader market fragility.

Counterpoint

Investors may be wary of the pending class‑action lawsuit and high valuation.

Key entities

  • Goldman Sachs

    Lead underwriter for Oura's IPO.

  • Eli Lilly

    Indicated interest to buy up to $100 million of Oura shares.

Related articles

$COINMedAI 8/10

Coinbase Opens IPO Access — Oura Is First, But There's a Catch

Coinbase launched a new service allowing eligible U.S. retail customers to request allocations in IPOs, starting with Oura's $2.2B IPO. Oura plans to sell 13.5M shares at $40-$44 each, with a fully diluted valuation of about $15.62B. Coinbase's IPO access prioritizes long-term investors, discouraging early selling.

$OURAHighAI 9/10

Smart ring maker Oura targets $2.2 billion in US listing

Oura Inc, a smart ring maker, aims to raise $2.2B in a US IPO, offering 50M shares at $40-$44 each. The company could be valued at $14.1B-$15B. Oura reported a $924.3M net loss on $1.21B revenue for the nine months ended June 30. The IPO is expected to price on September 29, with shares trading on Nasdaq under ticker OURA.

$COINHigh

Coinbase IPO News: US Retail Access Opens, With Oura Up First

Coinbase launched a feature allowing eligible US retail customers to request IPO shares, starting with Oura. Oura plans to offer 13.5M shares priced between $40 and $44, listing on Nasdaq as OURA. Coinbase's stock (COIN) rose 3.5% to $201.05 on the news, with a market cap of $53.04B. Oura's IPO is expected to price this week.

HighAI 8/10

Oura’s IPO seeks $2.2bn, and 73% of it goes to existing shareholders

Oura, a Finnish smart ring maker, launched its IPO, offering 50 million shares at $40-$44 each, potentially raising $2.2bn. The company will receive $594m, while existing shareholders will get $1.61bn. Oura plans to list on Nasdaq under the ticker OURA. The company's membership revenue grew 121% to $240.5m in nine months, with a gross margin of 89%. Oura guides towards 5.7 million paid members by the end of fiscal 2026.